Simcere Pharmaceutical Group Limited (HKG:2096)

HKG:2096 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,943	2,007	1,658	973.14	3,270
Short-Term Investments	-	11.14	964.23	1,210	-
Trading Asset Securities	-	-	-	-	3.63
Cash & Short-Term Investments	1,943	2,018	2,623	2,183	3,274
Cash Growth	-3.73%	-23.04%	20.12%	-33.31%	263.04%
Accounts Receivable	2,704	2,645	2,339	2,399	1,871
Other Receivables	-	50.73	39.89	37.37	43.79
Receivables	2,704	2,695	2,379	2,436	1,915
Inventory	593.65	770.14	371.59	290.96	311.13
Other Current Assets	224.59	155.13	85.61	69.24	967.03
Total Current Assets	5,466	5,639	5,458	4,980	6,467
Property, Plant & Equipment	2,270	2,170	2,139	1,931	2,128
Long-Term Investments	1,893	1,580	2,258	2,651	1,825
Goodwill	142.47	142.47	172.79	172.79	172.79
Other Intangible Assets	1,025	715.79	379.9	59.69	77.11
Long-Term Deferred Tax Assets	435.59	317	326.71	289.97	210.09
Other Long-Term Assets	178.19	188.95	53.79	76.56	63.53
Total Assets	11,510	10,854	10,789	10,161	10,943
Accounts Payable	275.73	317.22	335.43	323.95	242.08
Accrued Expenses	1,031	1,045	1,124	1,032	1,155
Short-Term Debt	1,050	762.43	1,184	991.57	1,561
Current Portion of Long-Term Debt	0.72	252.71	108.37	538.51	232.2
Current Portion of Leases	67.56	79.85	58.76	31.56	38.1
Current Income Taxes Payable	154.36	17.9	10.56	16.16	-
Current Unearned Revenue	28.16	43.31	63.34	26.14	18.76
Other Current Liabilities	119.25	167	82.41	103.7	249.91
Total Current Liabilities	2,727	2,686	2,967	3,064	3,497
Long-Term Debt	8.25	205.85	-	-	1,276
Long-Term Leases	82.42	128.4	155.92	74.24	193.43
Long-Term Unearned Revenue	377.69	393.11	403.35	417.61	447.95
Long-Term Deferred Tax Liabilities	72.7	102.68	115.29	142.77	193.6
Other Long-Term Liabilities	1,174	115	-	-	-
Total Liabilities	4,442	3,631	3,641	3,698	5,608
Common Stock	3,174	3,174	3,081	3,003	3,003
Retained Earnings	-	3,837	3,831	3,294	2,147
Comprehensive Income & Other	3,894	211.61	219.72	139.96	151.48
Total Common Equity	7,068	7,223	7,132	6,437	5,302
Minority Interest	-	-	16.06	25.76	33.94
Shareholders' Equity	7,068	7,223	7,148	6,463	5,336
Total Liabilities & Equity	11,510	10,854	10,789	10,161	10,943
Total Debt	1,209	1,429	1,507	1,636	3,300
Net Cash (Debt)	733.7	589.08	1,116	547.34	-26.14
Net Cash Growth	24.55%	-47.21%	103.86%	-	-
Net Cash Per Share	0.29	0.23	0.43	0.21	-0.01
Filing Date Shares Outstanding	2,474	2,617	2,660	2,628	2,609
Total Common Shares Outstanding	2,474	2,617	2,660	2,628	2,609
Working Capital	2,739	2,953	2,492	1,916	2,970
Book Value Per Share	2.86	2.76	2.68	2.45	2.03
Tangible Book Value	5,900	6,364	6,579	6,205	5,052
Tangible Book Value Per Share	2.39	2.43	2.47	2.36	1.94
Machinery	-	2,632	2,811	2,528	2,572
Construction In Progress	-	343.47	202.13	95.75	66.43

Updated Sep 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.